Patents Issued in July 16, 2020
-
Publication number: 20200224172Abstract: Methods and compositions for producing induced pluripotent stem cell by introducing nucleic acids encoding one or more transcription factors including Obox6 into a target cell.Type: ApplicationFiled: September 19, 2018Publication date: July 16, 2020Inventors: Geoffrey Schiebinger, Jian Shu, Marcin Tabaka, Brian Cleary, Aviv Regev, Eric S. Lander, Philippe Rigollet
-
Publication number: 20200224173Abstract: Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells.Type: ApplicationFiled: December 23, 2016Publication date: July 16, 2020Applicant: University of Florida Research Foundation, IncorporatedInventors: Nathalie Clement, Barry John Byme, Laura A. Small
-
Publication number: 20200224174Abstract: The disclosure provides methods for an in vitro evolution technique to identify and characterize mutations in the non-structural genes of an alphavirus replicon that increase the strength and persistence of expression of the replicon genome. Also provided herein are in vivo methods for administering to an animal model a mutated alphavirus replicon that codes for a gene of experimental or therapeutic interest in the subgenome of the alphavirus replicon. The mutations identified herein improve the therapeutic potential of self-replicating RNA, which may have implications for cancer immunotherapy and beyond, e.g., for vaccination or gene therapy.Type: ApplicationFiled: January 10, 2020Publication date: July 16, 2020Applicant: Massachusetts Institute of TechnologyInventors: Darrell J. Irvine, Ron Weiss, Yingzhong Li
-
Publication number: 20200224175Abstract: This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.Type: ApplicationFiled: January 21, 2020Publication date: July 16, 2020Applicant: Mayo Foundation for Medical Education and ResearchInventors: Mark J. Federspiel, Arun Ammayappan, Gennett Pike, Stephen James Russell
-
Publication number: 20200224176Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.Type: ApplicationFiled: February 2, 2018Publication date: July 16, 2020Applicants: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
-
Publication number: 20200224177Abstract: The present invention provides a stable cell line overexpressing a recombinant vitamin K-dependent (VKD) protein and both a recombinant vitamin K epoxide reductase (VKOR) and a recombinant vitamin K dependent gamma carboxylase (VKGC), wherein the amount of fully carboxylated VKD protein produced in the cell is increased 10% as compared to the amount of fully carboxylated VKD protein produced in the cell in the absence of the recombinant VKOR and the recombinant VKGC.Type: ApplicationFiled: August 27, 2019Publication date: July 16, 2020Inventors: Darrel W. Stafford, Tao Li
-
Publication number: 20200224178Abstract: An enzyme having the following characteristics of (a) and (b): (a) the enzyme has an activity of reversible dehydrogenation of D-amino acid; and (b) the enzyme is a hexamer of polypeptides having an amino acid sequence that has 80% or more identity with an amino acid sequence of SEQ ID NO: 2.Type: ApplicationFiled: August 9, 2018Publication date: July 16, 2020Applicants: Kureha Corporation, National Institute Of Advanced Industrial Science And TechnologyInventors: Hironaga AKITA, Yuusuke NAKAMICHI, Masahiro WATANABE, Akinori MATSUSHIKA, Tomotake MORITA
-
Publication number: 20200224179Abstract: A protease with a function of degrading carotenoids of scallop is provided, which belongs to the technical field of genetic engineering. In particular, the present invention relates to the sequence and application of a carotenoid oxidase gene of scallop. The present invention analyzes the gene sequence, and verifies that the gene has function of degrading carotenoids of scallop scallop by RNA interference technology, and can be used to increase the carotenoid content of the scallop muscle of scallop scallop. The gene verified that the gene expression products can degrade carotenoids accumulated in bacteria. In addition, the RNA interference method provides a powerful tool for the study of scallop functional genes; the prokaryotic expression and protein purification methods provided can efficiently prepare oxidative lyases of carotenoid in scallop, so as to provide necessary experimental tools for in-depth research of the mechanism of shell carotene metabolism.Type: ApplicationFiled: March 25, 2020Publication date: July 16, 2020Inventors: Xiaoli Hu, Zhenmin Bao, Huizhen Wang, Shuyue Wang, Xue Li, Liang Zhao, Mengran Zhang, Shanshan Lian, Tingting Li, Wei Wu, Shi Wang, Shiqi Liu, Lingling Zhang, Wei Lu
-
Publication number: 20200224180Abstract: The present invention relates to a recombinant host comprising a recombinant nucleic acid sequence encoding a polypeptide having at least about: a. 85% identity to the amino acid sequence set forth in SEQ ID NO: 1; b. 85% identity to the amino acid sequence set forth in SEQ ID NO: 3; c. 85% identity to the amino acid sequence set forth in SEQ ID NO: 6; d. 85% identity to the amino acid sequence set forth in SEQ ID NO: 9; e. 85% identity to the amino acid sequence set forth in SEQ ID NO: 11; f. 85% identity to the amino acid sequence set forth in SEQ ID NO: 14; g. 85% identity to the amino acid sequence set forth in SEQ ID NO: 17; h. 85% identity to the amino acid sequence set forth in SEQ ID NO: 20; i. 85% identity to the amino acid sequence set forth in SEQ ID NO: 22; or j. 85% identity to the amino acid sequence set forth in SEQ ID NO: 25.Type: ApplicationFiled: January 30, 2020Publication date: July 16, 2020Inventors: Viktor Marius BOER, Johannes Gustaaf Emst VAN LEEUWEN, Priscilla ZWARTJENS, Catharina Petronella Antonia Maria KOLEN
-
Publication number: 20200224181Abstract: The invention relates to mutant DNA polymerases of the Pol theta subfamily capable of performing non-templated nucleic acid extension, or of a functional fragment of such a polymerase, methods of producing these mutant DNA polymerases, kits and methods of using these mutant DNA polymerases.Type: ApplicationFiled: September 20, 2018Publication date: July 16, 2020Inventors: Marc DELARUE, Volahasina (Irina) RANDRIANJATOVO GBALOU
-
Publication number: 20200224182Abstract: The disclosure provides a method of producing recombinant alkaline phosphatase comprising: (i) culturing an alkaline phosphatase in a recombinant cell culture; (ii) obtaining a preparation of recombinant alkaline phosphatase from the cell culture; and (iii) minimizing in the preparation a concentration of at least one metal ion selected from the group consisting of: Nickel (Ni), Cobalt (Co), Copper (Cu), Manganese (Mn), Chromium (Cr), and Molybdenum (Mo).Type: ApplicationFiled: June 6, 2017Publication date: July 16, 2020Inventors: Saravanamoorthy RAJENDRAN, Rachael ALFORD, Sean GALLAGHER, Anne KANTARDJIEFF, Jared DAVIS
-
Publication number: 20200224183Abstract: An acid phosphatase mutant, and method for preparing nicotinamide riboside by same. The mutant is a protein of the following (a), (b) or (c): (a) a protein, having an amino acid sequence shown in SEQ ID NO: 3; (b) a protein, derived from (a), having catalytic activity higher than an acid phosphatase parent having an amino acid sequence shown in SEQ ID NO: 2, obtained by substituting, deleting or adding several amino acids in the amino acid sequence shown in SEQ ID NO: 3, using nicotinamide mononucleotide as a substrate; (c) a protein, having catalytic activity higher than the acid phosphatase shown in SEQ ID NO: 2, having 90% or more homology with the amino acid sequence of the protein defined by (a) or (b), and using nicotinamide mononucleotide as a substrate. It is used to prepare nicotinamide riboside and the conversion rate can be 99%.Type: ApplicationFiled: August 17, 2018Publication date: July 16, 2020Inventors: Rongzhao FU, Zhenwei LI, Min WANG, Xinglin GUO
-
Publication number: 20200224184Abstract: The present disclosure provides for compositions comprising a chimeric polypeptide comprising a polypeptide effective for treating glycogen storage disease and an internalizing moiety that promotes delivery into cells. In certain embodiments, the polypeptide effective for treating glycogen storage disease is an acid alpha-glucosidase (GAA), a laforin, an amyloglucosidase (AGL), a malin, or an alpha amylase. The present disclosure also provides for methods for decreasing glycogen accumulation in cells or for treating glycogen storage diseases, including Forbes-Cori Disease, Andersen Disease, von Gierke Disease, Pompe Disease, and Lafora Disease, comprising administering the chimeric polypeptide disclosed herein.Type: ApplicationFiled: February 11, 2019Publication date: July 16, 2020Inventor: Dustin D. Armstrong
-
Publication number: 20200224185Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.Type: ApplicationFiled: July 7, 2017Publication date: July 16, 2020Applicant: Children's Medical Center CorporationInventors: Min Dong, Sicai Zhang, Paul Stenmark
-
Publication number: 20200224186Abstract: The application discloses multimeric assemblies including multiple oligomeric substructures, where each oligomeric substructure includes multiple proteins that self-interact around at least one axis of rotational symmetry, where each protein includes one or more polypeptide-polypeptide interface (“O interface”); and one or more polypeptide domain that is capable of effecting membrane scission and release of an enveloped multimeric assembly from a cell by recruiting the ESCRT machinery to the site of budding by binding to one or more proteins in the eukaryotic ESCRT complex (“L domain”); and where the multimeric assembly includes one or more subunits comprising one or more polypeptide domain that is capable of interacting with a lipid bilayer (“M domain”), as well as membrane-enveloped versions of the multimeric assemblies.Type: ApplicationFiled: November 6, 2019Publication date: July 16, 2020Inventors: Neil KING, Wesley SUNDQUIST, Joerg VOTTELER, Yang HSIA, David BAKER, Jacob BALE, Marc LAJOIE, Gabriel BUTTERFIELD, Elizabeth GRAY, Daniel STETSON
-
Publication number: 20200224187Abstract: The present invention relates to polypeptide, preferably to a glucose isomerase, comprising an amino acid sequence, wherein the amino acid sequence of the polypeptide, preferably the glucose isomerase, is at least 95% identical to an amino acid sequence of SEQ ID NO:1, wherein the amino acid sequence of the polypeptide, preferably the glucose isomerase, comprises an amino acid substitution at one or more amino acid positions, wherein the one or more amino acid positions is/are each and independently selected from the group consisting of SEQ ID NO: 1 amino acid positions 89, 90, 95, 0, 33, 34, 35, and 59. The present invention further relates to methods preparing glucose including the use of the polypeptides of the invention for preparing glucose.Type: ApplicationFiled: May 4, 2018Publication date: July 16, 2020Inventors: Birgit Brucher, Andreas Vogel, Hanna Maria Dudek, Rico Czaja
-
Publication number: 20200224188Abstract: A well for electrically stimulating at least one cell. The well includes a bottom portion and comprises an adaptive electrode arrangement for introducing an electric field into the well. The adaptive electrode arrangement includes a pair of electrodes disposed within the well. Each electrode of the pair of electrodes has a distal end and is independently and axially displaceable relative to the other electrode and the bottom portion of the well. The distal end of each electrode of the pair of electrodes is in contact with the bottom portion of the well, ensuring a uniform and constant electric field is applied within the well.Type: ApplicationFiled: August 7, 2018Publication date: July 16, 2020Inventors: Chuck Z. Li, Brandon Zachary Sarich, Phillip Ng
-
Publication number: 20200224189Abstract: Provided is a composition for preserving cell-free nucleic acids and/or cells in a biological sample and methods for use thereof. The composition comprises at least one volume excluding polymer, at least one osmotic agent and at least one enzyme inhibitor. The composition optionally further comprises at least one metabolic inhibitor. Further, provided is a kit comprising the composition, preferably in a blood collection tube, or the components of the composition.Type: ApplicationFiled: May 16, 2017Publication date: July 16, 2020Applicant: Norgen Biotek Corp.Inventors: Taha Alexander HAJ-AHMAD, Yousef HAJ-AHMAD
-
Publication number: 20200224190Abstract: The present disclosure provides methods for selectively tagging 5-methylcytosine in a DNA sample and using this approach for genome-wide profiling of 5-methylcytosine in a low input DNA sample such as circulating cell-free DNA.Type: ApplicationFiled: September 11, 2018Publication date: July 16, 2020Inventors: Chunxiao Song, Paulina Siejka
-
Publication number: 20200224191Abstract: The present disclosure provides synthetic modular polypeptide libraries and nucleic acids encoding such synthetic modular polypeptide libraries. Also provided are methods of making synthetic modular polypeptide libraries and nucleic acids encoding synthetic modular polypeptide libraries. Methods of screening a synthetic modular polypeptide library to identify a selected phenotype associated with a member of a synthetic modular polypeptide library are also provided where such methods find use in both in vitro and in vivo assays.Type: ApplicationFiled: August 31, 2016Publication date: July 16, 2020Inventors: Wendell A. Lim, Scott M. Coyle, Russell M. Gordley, Kole T. Roybal
-
Publication number: 20200224192Abstract: Provided are a method and a kit for constructing a simplified genomic library. The method comprises: performing a non-specific amplification on a whole genome with a first pair of primers to obtain random amplified fragments; performing a specific amplification on the random amplified fragments with a second pair of primers to obtain the simplified genomic library.Type: ApplicationFiled: January 26, 2018Publication date: July 16, 2020Inventors: Kejian WANG, Qing LIU
-
Publication number: 20200224193Abstract: The present invention relates to a method of manufacturing vesicles by delivery of RNA nanoparticles, in which messenger RNA nanoparticles for target protein expression are delivered to a cell, and vesicles manufactured using the same. A protein is locally over-expressed in the cell to thus be excreted through the vesicles to the outside of the cell, which enables the vesicles containing a target protein to be easily mass-produced. The vesicles containing the target protein is obtained regardless of the cell type. The concentration of the messenger RNA nanoparticles delivered to the cell is adjusted, thus adjusting the manufacturing amount and the manufacturing time of the vesicles. After the surface of the cell is reformed, the messenger RNA nanoparticles are delivered thereto, thus obtaining the vesicles carrying the target protein and having a surface property of a specific function.Type: ApplicationFiled: October 8, 2019Publication date: July 16, 2020Inventors: Jong-Bum LEE, Hye-Jin Kim
-
Publication number: 20200224194Abstract: Nucleic acid expression systems are provided herein that include a first synthetic oligonucleotide comprising a payload sequence and a second synthetic oligonucleotide comprising a sequence that encodes a helper polypeptide. Compositions (e.g., pharmaceutical compositions) comprising the nucleic acid expression systems as well as methods of using the same are also provided herein.Type: ApplicationFiled: September 20, 2018Publication date: July 16, 2020Inventors: Nikolai Eroshenko, Nikhil Dhar, Taylor Gill, Marianna Keaveney, Hannu Rajaniemi
-
Publication number: 20200224195Abstract: An agent capable of decreasing the activity of FAM46A for use in supporting weight maintenance and/or treating or preventing obesity.Type: ApplicationFiled: November 29, 2017Publication date: July 16, 2020Inventors: Jerome Carayol, Armand Valesia, Jorg Hager
-
Publication number: 20200224196Abstract: The invention provides a single-stranded oligonucleotide represented by the formula [Xz-Lx]m-X-Y-[Ly-Yz]n, wherein X is represented by Xa-Xb, Xa is coupled with Y, and Xb and Y hybridize. Xa is composed of 1 to 40 nucleotides and contains at least one modified-nucleotide. Xb is composed of 4 to 40 nucleotides and contains at least one modified-nucleotide. Y is composed of 4 to 40 nucleotides and contains at least one ribonucleotide. Xz and Yz are composed of 5 to 40 nucleotides and contain at least one modified-nucleotide. Nucleotide sequences X, Xz and Yz have an antisense sequence capable of hybridizing with a target RNA. Lx and Ly are composed of 0 to 20 nucleotides.Type: ApplicationFiled: July 26, 2018Publication date: July 16, 2020Applicant: NISSAN CHEMICAL CORPORATIONInventors: Yusuke IRIYAMA, Hiroyuki NAKAJIMA, Tatsuro KANAKI
-
Publication number: 20200224197Abstract: There is disclosed a trans-acting functional nucleic acid molecule comprising a eukaryotic target binding sequence comprising a sequence reverse complementary to a target mRNA sequence for which protein translation is to be enhanced, and a regulatory sequence comprising an internal ribosome entry site (IRES) sequence or an internal ribosome entry site (IRES) derived sequence and enhancing translation of the target mRNA sequence, wherein the regulatory sequence is located 3? of the target binding sequence.Type: ApplicationFiled: September 20, 2018Publication date: July 16, 2020Applicants: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATIInventors: Stefano GUSTINCICH, Silvia ZUCCHELLI
-
Publication number: 20200224198Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.Type: ApplicationFiled: March 2, 2020Publication date: July 16, 2020Applicant: IONIS PHARMACEUTICALS, INC.Inventors: Thazha P. PRAKASH, Punit P. SETH, Eric E. SWAYZE
-
Publication number: 20200224199Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.Type: ApplicationFiled: March 13, 2020Publication date: July 16, 2020Inventors: Michael Luzzio, Kathleen Mccarthy, William Haney
-
Publication number: 20200224200Abstract: Embodiments of the disclosure relate to modulation of an immune response comprising modulating the interaction between a death associated protein kinase (DAPK) and stimulator of interferon genes protein (STING) pathway. In certain embodiments, a method is provided for treating a subject for an inflammatory or autoimmune disease, or cancer, or a side effect or symptom thereof by administering an agent that modulates the interaction between a DAPK and the STING pathway.Type: ApplicationFiled: September 25, 2018Publication date: July 16, 2020Inventors: Sonia SHARMA, Mariko TAKAHASHI
-
Publication number: 20200224201Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting epression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.Type: ApplicationFiled: December 12, 2019Publication date: July 16, 2020Inventors: William Querbes, Kevin Fitzgerald, James Butler, Stephanie Williams, Gregory Hinkle, Martin A. Maier
-
Publication number: 20200224202Abstract: The present invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of an ectonucleotidase (NTPdase; CD73) of SEQ ID NO.1 (human), wherein the oligonucleotide inhibits at least 50% of the CD39 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.Type: ApplicationFiled: October 9, 2017Publication date: July 16, 2020Inventors: Frank JASCHINSKI, Tamara THELEMANN
-
Publication number: 20200224203Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.Type: ApplicationFiled: February 4, 2020Publication date: July 16, 2020Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
-
Publication number: 20200224204Abstract: The present disclosure relates to compounds, compositions, and methods for the induction of membraneless organelles.Type: ApplicationFiled: August 17, 2018Publication date: July 16, 2020Inventors: Christopher James DONNELLY, Joseph Patrick CLARKE
-
Publication number: 20200224205Abstract: The invention relates to virus like particles (VLP) associated with a lysosomal enzyme or an expression vector encoding a lysosomal enzyme which are used in a method for the treatment of a lysosomal storage disease. The invention also relates to a pharmaceutical composition for use in a method for the treatment of a lysosomal storage disease, to an expression vector encoding a lysosomal enzyme and to a method of associating a VLP with an expression vector encoding a lysosomal enzyme.Type: ApplicationFiled: December 17, 2019Publication date: July 16, 2020Applicant: NEUWAY Pharma GmbHInventors: Victoria DEMINA, Marcus STAPF, Sergey Sotnikov, Heiko MANNINGA
-
Publication number: 20200224206Abstract: Provided herein are non-plasmid derived DNA vaccines comprised solely of enzymatically produced amplicon expression vectors and their method of use to elicit antigen-specific immune responses in a subject. The enzymatically produced amplicon expression vectors may be specifically utilized as a DNA based cancer vaccine to express desired antigens or other immunogenic polypeptides within a subject to induce a specific anti-cancer antigen-specific immune response. The enzymatically produced amplicon expression vectors may also be utilized to express cancer-specific neoantigens.Type: ApplicationFiled: December 5, 2019Publication date: July 16, 2020Inventors: Michael E. Hogan, Stephen Hughes, Antonella Conforti, Luigi Aurisicchio, Fabio Palombo
-
Publication number: 20200224207Abstract: The present invention provides a method of producing linear or circular DNA by joining two or more types of DNA fragments to each other at regions having homologous base sequences, and a DNA fragment-joining kit used in the method. The present invention provides a DNA production method comprising producing linear or circular DNA by joining the two or more types of DNA fragments to each other at regions having homologous base sequences or regions having complementary base sequences in the reaction solution.Type: ApplicationFiled: July 5, 2018Publication date: July 16, 2020Inventors: Masayuki SUETSUGU, Tatsuaki KURATA
-
Publication number: 20200224208Abstract: The present disclosure relates to engineered cells that include genetic alterations leading to up- or down-regulation of certain genes in the cells for improved production of a recombinant protein. Also provided are methods of preparing and using such cells.Type: ApplicationFiled: January 2, 2020Publication date: July 16, 2020Inventors: Amita Goel, Nikhil Goel
-
Publication number: 20200224209Abstract: The present disclosure concerns recombinant microbial host cell having, in glycolytic conditions, increased glycerol importing activity glycerol as well as, in high osmotic conditions, a decreased NAD-dependent glycerol-3-phosphate dehydrogenase (GPD) activity. The recombinant microbial host cell is particularly useful for the fermentation of sugarcane- or molasses-based medium for the production of ethanol.Type: ApplicationFiled: May 23, 2018Publication date: July 16, 2020Inventors: Emily Agnes Stonehouse, John Evan Eck McBride, Kristen M. Deleault, Zachary Losordo, Mitchell Codd
-
Publication number: 20200224210Abstract: Methods of making haploid plants.Type: ApplicationFiled: March 29, 2018Publication date: July 16, 2020Inventor: Arundhati MAHESHWARI
-
Publication number: 20200224211Abstract: Transgenic seed for crops with improved traits are provided by trait-improving recombinant DNA in the nucleus of cells of the seed where plants grown from such transgenic seed exhibit one or more improved traits as compared to a control plant. Of particular interest are transgenic plants that have increased yield. The present invention also provides recombinant DNA molecules for expression of a protein, and recombinant DNA molecules for suppression of a protein.Type: ApplicationFiled: December 20, 2019Publication date: July 16, 2020Inventors: Mark Scott Abad, Marie Coffin, Barry S. Goldman
-
Publication number: 20200224212Abstract: Methods and materials for modulating heat and/or drought tolerance in plants are disclosed. For example, nucleic acids encoding heat and/or drought-tolerance polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased heat and/or drought tolerance and plant products produced from plants having increased heat and/or drought tolerance.Type: ApplicationFiled: February 13, 2020Publication date: July 16, 2020Inventors: Cory Christensen, Wuyi Wang, Dennis Yang
-
Publication number: 20200224213Abstract: The invention provides recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the recombinant DNA molecules operably linked to heterologous transcribable DNA molecules, as are methods of their use.Type: ApplicationFiled: January 9, 2020Publication date: July 16, 2020Inventor: Stanislaw Flasinski
-
Publication number: 20200224214Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.Type: ApplicationFiled: October 7, 2015Publication date: July 16, 2020Applicant: Dow AgroSciences LLCInventors: Kenneth E. Narva, Huarong Li, Chaoxian Geng, Navin Elango, Marrhew J, Henry, Murugesan Rangasamy, Aaron T. Woosley, Kanika Arora, Premchand Gandra, Sarah E. Worden, Elane Fishilevich
-
Publication number: 20200224215Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.Type: ApplicationFiled: October 7, 2015Publication date: July 16, 2020Applicant: Dow AgroSciences LLCInventors: Kenneth E. Narva, Huarong Li, Murugesan Rangasamy, Kanika Arora, Premchand Gandra, Sarah E. Worden, Elane Fishilevich
-
Publication number: 20200224216Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.Type: ApplicationFiled: January 11, 2018Publication date: July 16, 2020Applicant: PIONEER HI-BRED INTERNATIONAL, INC.Inventors: NURIA JIMENEZ-JUAREZ, ALBERT L LU, LU LIU, MARK EDWARD NELSON, GUSUI WU
-
Publication number: 20200224217Abstract: The present disclosure provides a promoter having at least the core components of a duck retinoic acid-inducible gene I (RIG-I) promoter, as well as expression constructs having the duck RIG-I promoter operably linked to a gene product-encoding nucleic acid (e.g., an avian RIG-I protein), and recombinant host cells containing the duck RIG-I promoter, e.g., in such expression constructs. The present disclosure also provide animals genetically modified to have a gene encoding a duck RIG-I promoter operably linked to a gene product-encoding nucleic acid (e.g., an avian RIG-I protein, such as a duck RIG-I protein).Type: ApplicationFiled: September 28, 2017Publication date: July 16, 2020Inventors: Katharine MAGOR, Yanna XIAO
-
Publication number: 20200224218Abstract: A method is provided to enhance repair or regeneration of a mammalian cardiovascular system to include heart and/or vasculature comprising: administering to a mammal in need thereof a composition comprising an effective amount of an agent that elevates levels of Smo, Ptc1, Shh, Ihh, Dhh, Gli1, Gli2, or Mycn,Type: ApplicationFiled: July 23, 2019Publication date: July 16, 2020Inventors: Daniel J. Garry, Mary G. Garry, Bhairab Singh
-
Publication number: 20200224219Abstract: In a first aspect, the present invention relates to a mutated adeno-associated virus (AAV) capsid protein or fragment thereof wherein a substitution of a wild type non-cysteine amino acid into a cysteine is present whereby the wild type non-cysteine amino acid is exposed on the outer surface of the capsid of an AAV particle. In a further aspect, a mutated AAV particle comprising the AAV capsid protein or fragment thereof according to the present invention is provided. In addition, a nucleic acid encoding the AAV capsid protein according to the present invention is identified together with a corresponding nucleic acid vector, in particular, a plasmid or a gene string. In addition, a host cell containing the nucleic acid vector or the nucleic acid according to the present invention as well as a composition comprising at least an infectious (transducing) AAV particle containing a mutated AAV capsid protein as defined herein together with a non-infectious AAV particle containing a mutated AAV capsid protein as e.Type: ApplicationFiled: September 28, 2018Publication date: July 16, 2020Inventors: Hildegard BÜNING, Anke HUBER, Luca PERABO
-
Publication number: 20200224220Abstract: The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.Type: ApplicationFiled: July 13, 2018Publication date: July 16, 2020Inventors: Mitchell H. FINER, Edward M. KENNEDY, Lorena LERNER
-
Publication number: 20200224221Abstract: The present invention relates to the field of genetic engineering. In particular, the present invention relates to a genome editing method with high efficiency and high specificity. More specifically, the present invention relates to a method for increasing the efficiency of site-directed modification of a target sequence in a genome of an organism by a high-specificity Cas9 nuclease variant.Type: ApplicationFiled: February 22, 2018Publication date: July 16, 2020Applicant: Institute of Genetics and Developmental Biology, Chinese Academy of SciencesInventors: Caixia GAO, Huawei ZHANG, Dingbo ZHANG